Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries

Introduction: Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to Central and Eastern European (CEE) countries.Areas covered: After screening 376 abstracts, 42 articles were included in the...